POROGEN EFFECTS ON AEROSOLIZATION PROPERTIES OF FLUCONAZOLE LOADED PLGA LARGE POROUS PARTICLES
Objective: The most common fungal infection, which is usually occurs in immunocompromised patients, is pulmonary cryptococcosis. Fluconazole (FLZ) is a first-generation triazole which is used for the treatment of pulmonary cryptococcal infection during 6-12 mo. A non-invasive and targeted medication delivery to lung is highly desirable due to lower delivered dose and reduced systemic effects. Large Porous Particles (LPPs) have shown lower phagocytic clearance and higher bioavailability compared to non-porous particles of the same size with a remarkable safety profile.
Methods: In the present study, the effect of two different porogen agents with different mechanisms on FLZ loaded PLGA LPPs properties were evaluated using design expert software®. These properties included volume diameter, drug loading, encapsulation efficiency, mass median aerodynamic diameter (MAAD), geometric standard deviation (GSD) and fine particle fraction (FPF).
Results: All FLZ-loaded PLGA LPPs (FLZ-PLGA LPPs) showed acceptable volume diameter, drug loading and encapsulation efficiency with rapid FLZ release due to macroporous structure. Significant differences in aerosolization properties in which MAAD, GSD and FPF optimized formulation of the optimized formulation were 6.71±0.4 µm, 1.65±0.08 and 33.20±1.7%, respectively.
Conclusion: It was suggested that gas foamed preparation technique using ammonium bicarbonate was a better technique to produce FLZ loaded PLGA LPPs with more suitable in vitro respirable properties.
2. Naggie S, JR Perfect. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med 2009;30:337-53.
3. Li L, L Zhuang, J Zhou, C Shao. Pulmonary cryptococcosis coexisting with adenocarcinoma: a case report and review of the literature. J Med Case Reports 2018;12:327.
4. Ribas E Ribas AD, P Spolti, EM Del Ponte, KZ Donato, H Schrekker, AM Fuentefria. Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini-review. Braz J Microbiol 2016;47:793-9.
5. Garbuzenko OB, M Saad, S Betigeri, M Zhang, AA Vetcher, VA Soldatenkov, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2008;26:382-94.
6. Alipour S, H Montaseri, A Khalili, M Tafaghodi. Non-invasive endotracheal delivery of paclitaxel-loaded alginate microparticles. J Chemother 2016;28:411-6.
7. Arafa M, B Ayoub. Nano-vesicles of salbutamol sulphate in metered-dose inhalers: formulation, characterization and in vitro evaluation. Int J Appl Pharm 2017;9:100-5.
8. Hu Y, M Li, M Zhang, Y Jin. Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles. Int J Pharm 2018;551:212-22.
9. Lee J, YJ Oh, SK Lee, KY Lee. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J Controlled Release 2010;146:61-7.
10. Yang Y, N Bajaj, P Xu, K Ohn, MD Tsifansky, Y Yeo. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009;30:1947-53.
11. Edwards DA, J Hanes, G Caponetti, J Hrkach, A Ben Jebria, ML Eskew, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1688-71.
12. Oh YJ, J Lee, JY Seo, T Rhim, SH Kim, HJ Yoon, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Controlled Release 2011;150:56-62.
13. Nasr M, GAS Awad, S Mansour, I Taha, AA Shamy, ND Mortada. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting. Eur J Pharm Biopharm 2011;79:601-11.
14. Ungaro F, G De Rosa, A Miro, F Quaglia, MI La Rotonda. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006;28:423-32.
15. Kim I, HJ Byeon, TH Kim, ES Lee, KT Oh, BS Shin, et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012;33:5574-83.
16. Chow A, H Tong, P Chattopadhyay, B Shekunov. Particle engineering for pulmonary drug delivery. Pharm Res 2007;24:411-37.
17. Rajendran R, R Balan, N Ganesan, D Thiruvengadam. Recent modalities in drug delivery via inhalation therapy–an advanced treatment strategy for pulmonary carcinoma. Int J Pharm Pharm Sci 2015;7:8-21.
18. Vakilinezhad MA, A Amini, T Dara, S Alipour. Methotrexate and curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: in vitro and in vivo evaluation. Colloids Surfaces B 2019;184:1105-15.
19. Koshkina NV, JC Waldrep, LE Roberts, E Golunski, S Melton, V Knight. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7:3258-62.
20. Kim TK, JJ Yoon, DS Lee, TG Park. Gas foamed open porous biodegradable polymeric microspheres. Biomaterials 2006;27:152-9.
21. Parhizkar E, L Emadi, S Alipour. Development and evaluation of midazolam in situ nasal gel properties in presence of solubility enhancers at cilia-friendly pH. Macromol Res 2017;25:225-61.
22. Seema Kohli, Abhisek Pal, S Jain. Preparation, characterization and evaluation of poly (lactide-co-glycolide) microspheres for the controlled release of zidovudin. Int J Pharm Pharm Sci 2017;9:70-7.
23. Doan TVP, JC Olivier. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as an aerosol by premix membrane homogenization. Int J Pharm 2009;382:61-6.
24. Ungaro F, C Giovino, C Coletta, R Sorrentino, A Miro, F Quaglia. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pharm Sci 2010;41:60-70.
25. Ungaro F, I d'Angelo, A Miro, MI La Rotonda, F Quaglia. Engineered PLGA nano-and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012;64:1217-35.
26. Rivera PA, MC Martinez Oharriz, M Rubio, JM Irache, S Espuelas. Fluconazole encapsulation in PLGA microspheres by spray-drying. J Microencapsul 2004;21:203-11.
27. Arnold MM, EM Gorman, LJ Schieber, EJ Munson, C Berkland. Nano cipro encapsulation in monodisperse large porous PLGA microparticles. J Controlled Release 2007;121:100-9.
28. Ansary RH, MB Awang, MM Rahman. Biodegradable poly(D,L-lactic-co-glycolic acid)-based micro/nanoparticles for sustained release of protein drugs-a review. Trop J Pharm Res 2014;13:1179-90.
29. Makadia HK, SJ Siegel. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011;3:1377-97.
30. El-Gendy N, C Berkland. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 2009;26:1752-63.
31. Naikwade S, A Bajaj, P Gurav, M Gatne, P Singh Soni. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation and in vivo efficacy study. AAPS PharmSciTech 2009;10:993-1012.
32. Liu XB, JX Ye, LH Quan, CY Liu, XL Deng, M Yang, et al. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. Eur J Pharm Biopharm 2008;70:845-52.
33. Lin HR, CJ Kuo, CY Yang, SY Shaw, YJ Wu. Preparation of macroporous biodegradable PLGA scaffolds for cell attachment with the use of mixed salts as porogen additives. J Biomed Mater Res 2002;63:271-9.
34. Zheng WW, L Zhao, YM Wei, Y Ye, SH Xiao. Preparation and the in vitro Evaluation of the nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull 2010;58:1015-9.
This work is licensed under a Creative Commons Attribution 4.0 International License.